title: New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.
abstract: BACKGROUND
  Antiangiogenic strategies are affording considerable interest and have become a major milestone in therapeutics of various adult cancers. However, progress has been slow to expand such therapies to patients with pediatric solid malignancies.
  
  
  METHODS
  This review discusses the principal pathways for angiogenesis in pediatric solid malignancies and summarizes recent preclinical and clinical data on antiangiogenesis strategies in these tumors.
  
  
  RESULTS
  The reader will gain state-of-the-art knowledge in the current advancements of antiangiogenic therapies in pediatric clinical trials in regard to supporting preclinical data, and in the status of potential biomarkers investigated for monitoring angiogenesis inhibitors. Mechanisms of resistance to antiangiogenic therapy will also be discussed. Finally, we describe our experience in the monitoring of circulating endothelial cells and progenitors and their potential role as biomarkers of metastatic disease and resistance to antiangiogenic therapies.
  
  
  CONCLUSIONS
  Evaluation and development of antiangiogenesis protocols are starting and represent a crucial step in the management of pediatric solid malignancies today. Emphasis should be placed on the development of proper surrogate markers to monitor antiangiogenic activity and on the possible long-term effects of these therapies in a pediatric population.
authors.affiliation: Translational Research Laboratory, Institut Gustave Roussy, Villejuif, France. melissa.taylor@apr.aphp.fr
authors.forename: Melissa
authors.initials: M
authors.lastname: Taylor
authors.forename: Jochen
authors.initials: J
authors.lastname: Rössler
authors.forename: Birgit
authors.initials: B
authors.lastname: Geoerger
authors.forename: Gilles
authors.initials: G
authors.lastname: Vassal
authors.forename: Françoise
authors.initials: F
authors.lastname: Farace
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D015415:Biomarkers / Q000032:analysis; D002465:Cell Movement / Q000187:drug effects; D002648:Child; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D042783:Endothelial Cells / Q000187:drug effects; D006801:Humans; D009389:Neovascularization, Pathologic / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D015415:Biomarkers; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor